Arca
Skip to content
Tools
Tools

ABAT: 4-aminobutyrate aminotransferase, mitochondrial

Catalyzes the conversion of gamma-aminobutyrate and L-beta- aminoisobutyrate to succinate semialdehyde and methylmalonate semialdehyde, respectively.

  • Drugs that act on it: 1
  • Approved: 1
  • In phases 1 to 3: 0
  • Sponsors: 1

Who is on it, and how far along

Every drug ChEMBL records acting on ABAT, by the furthest stage it has reached for any use, coloured by modality.

How to read this

Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.

  • Small molecule 1

Approved1

  • Vigabatrin

Phase 30

    Phase 20

      Phase 10

        The landscape

        Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials.
        DrugFurthest stageSponsorModalityActionOpen trials
        VigabatrinBoxed warningApprovedLundbeckSmall moleculeInhibitorGamma-amino-N-butyrate transaminase inhibitor2

        Open trials

        The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 2 in all, from ClinicalTrials.gov.
        Efficacy and Safety of Rapamycin Versus Vigabatrin in the Prevention of Tuberous Sclerosis Complex Symptoms in InfantsVigabatrinPhase 2 / Phase 3RecruitingKatarzyna KotulskaAug 3, 2021
        Vigabatrin With High Dose Prednisolone Combination Therapy vs Vigabatrin Alone for Infantile SpasmVigabatrinNot applicableRecruitingKullasate SakpichaisakulMar 10, 2020

        Diseases most associated with it

        Open Targets association score, 0 to 1; all associations
        GABA aminotransaminase deficiency
        0.80
        Mitochondrial DNA depletion syndrome
        0.54
        Focal impaired awareness seizure
        0.47
        Complex partial epilepsy
        0.46
        Global developmental delay
        0.37
        Focal epilepsy
        0.37
        Hereditary disease
        0.34
        Cocaine dependence
        0.22
        Systemic inflammatory response syndrome
        0.20

        Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL2044, ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov, checked daily; this page as of 2026-11-18. Gene name, function (UniProt P80404, CC BY 4.0) and disease associations are from Open Targets (CC0). ChEMBL and Open Targets

        Logos are each company's own site icon, matched by name through Wikidata.Company names and logos identify the companies in public FDA and registry records and do not imply endorsement.